Perspective Therapeutics
CATX
42 hedge funds and large institutions have $17.8M invested in Perspective Therapeutics in 2023 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 13 closing their positions.
2,234% more capital inflows, than outflows
Capital inflows: $4.63M | Capital outflows: $198K
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
2.13% less ownership
Funds ownership: 12.13% → 10% (-2.1%)
13% less funds holding
Funds holding: 48 → 42 (-6)
46% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.43M |
| 2 |
BlackRock
New York
|
+$1.04M |
| 3 |
Osterweis Capital Management
San Francisco,
California
|
+$646K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$295K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$61.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$75.5K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$32.4K |
| 3 |
Virtu Financial
New York
|
-$17K |
| 4 |
Jane Street
New York
|
-$12.2K |
| 5 |
Perkins Capital Management
Wayzata,
Minnesota
|
-$9.39K |
CATX Hedge Fund Activity: Q1 2023 in Review
42 of the 6,289 institutional investors tracked by Wall St. Rank reported a position in Perspective Therapeutics (CATX) for Q1 2023, worth a combined $17.8M — up 317% from $4.26M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of CATX and 7 opened new positions — a net loss of 6 holders — while 6 trimmed existing stakes and 9 added.
The largest buyer was Vanguard Group, adding an estimated $2.43M. The largest seller was Citadel Advisors, exiting entirely with an estimated $75.5K sold.
- 42 institutional investors held Perspective Therapeutics (CATX) as of Q1 2023, down from 48 in Q4 2022.
- Funds reported $17.8M of Perspective Therapeutics stock for Q1 2023, up 317% quarter-over-quarter.
- 7 funds opened new Perspective Therapeutics positions in Q1 2023 and 13 closed out, a net change of -6 holders.
- The largest Perspective Therapeutics buyer in Q1 2023 was Vanguard Group, an estimated $2.43M added.
- The largest Perspective Therapeutics seller in Q1 2023 was Citadel Advisors, an estimated $75.5K sold.
Based on aggregated 13F filings for Q1 2023.